Phase 2Completed
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients
- Sponsor
- Larysa Sanchez (Academic or other)
- Enrolment
- 20 enrolled
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- Daratumumab; Bortezomib; Lenalidomide; Dexamethasone; Ixazomib
- Ages
- older adults
- Registry
- NCT04052880
Full record on ClinicalTrials.gov
From the registry
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the study, subjects will be monitored closely for adverse events, laboratory abnormalities, and clinical response.
Primary outcomes
- Responses: VGPR or better
History
Last registry update
Study completion
Primary completion
Started
Registered